Although Incyte (INCY) already has an oncology product on the market (Jakafi), it’s what’s in the pipeline that could quietly be making INCY one of the better acquisition targets among biotech stocks right now.
Jakafi (ruxolitinib) is in clinical trials as a treatment for pancreatic cancer as well as other malignancies, while INCB-39110 and baricitinib are both in latter-stage trials as therapies for myelofibrosis and rheumatoid arthritis, respectively. If all goes well in the fourteen different clinical trials Incyte is conducting at this time, the potential revenue of its pipeline totals in the billions, annually.
The nice part for newcomers is that the company has remained on the fringe of the media’s spotlight, so there’s still plenty of value for INCY stock yet to materialize. It’s an easy addition to anyone’s list of biotech stocks that are also buyout targets.